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PROGRESSION OF NON-SMALL-CELL LUNG CANCER DURING 
THE INTERVAL BEFORE STEREOTACTIC BODY RADIOTHERAPY 
 
With the development and establishment of stereotactic body radiotherapy (SBRT), 
increasing numbers of patients with stage I non-small-cell lung cancer (NSCLC) who are 
medically inoperable or refuse surgery are now treated with SBRT (1-5). The influence of 
WT in the treatment of NSCLC on survival remains poorly understood, although many 
studies focusing on this issue have been performed. The British Thoracic Society 
recommended a WT of no longer than 4 weeks between acceptance onto a surgeon's 
waiting list and thoracotomy in operable NCSLC patients (6). However, this 
recommendation was only derived from analysis of expert committee reports and the 
clinical experience of respected authorities. Therefore, the length of time that is acceptable 
for stage I NSCLC has not yet been clarified. To investigate the relationship between 
waiting time (WT) and disease progression in patients undergoing stereotactic body 
radiotherapy (SBRT) for lung adenocarcinoma (AD) or squamous cell carcinoma (SQ). 
167 patients with stage I AD or SQ undergoing SBRT between January 2004 and 
September 2009 were analyzed. The WT was defined as the interval between diagnostic CT 
before referral and CT for treatment planning or positioning before SBRT. Tumor size was 
measured on the slice of the longest tumor diameter and tumor volume was calculated from 
the longest diameter and diameter perpendicular to it. Changes in tumor volume and TNM 
stage progression were evaluated, and volume doubling time (VDT) was estimated. 
The median WT was 39 days (range: 5-323 days). There was a correlation between WT and 
rate of increase in volume in SQ, but not in AD. The median VDTs of AD and SQ were 156 
and 97 days, respectively. Thirty tumors (23%) did not show volume increase during WTs > 
25 days. In 35 patients waiting for < 4 weeks, no patient showed T-stage progression, 
whereas in 18 of 95 (19%) patients waiting for > 4 weeks, T-stage progressed from T1 to 
T2 (p = 0.003). In 7 of 89 (7.9%) T1 ADs and 11 of 41 (27%) T1 SQs, T-stage progressed 
(p = 0.006). N-stage and M-stage progressions were not observed. 
The WT appears to be more important in SQ than in AD. Generally, a WT of < 4 weeks 
 appears acceptable. 
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